What Causes Heart Calcification in Fetus?

Fetal heart calcification results from abnormal calcium deposits forming within the muscle, valves, or lining of a developing baby’s heart, and it can be triggered by infections, maternal autoimmune antibodies, rare genetic disorders, certain drug exposures, or conditions that cut off blood flow to heart tissue. The finding on prenatal ultrasound is uncommon but tends to signal serious underlying disease, with significant cardiac dysfunction reported in most documented cases.¹ Because so many different conditions can lead to the same endpoint, pinpointing the cause in any individual pregnancy requires careful diagnostic work.

How Calcium Ends Up in Heart Tissue

In general cardiology, two broad mechanisms explain why calcium shows up where it should not. The first is called dystrophic calcification: tissue that has already been damaged or killed attracts calcium deposits even when overall calcium and phosphate levels in the blood are normal. The second is metastatic calcification, which happens when there is too much calcium or phosphate circulating systemically, and minerals settle into otherwise healthy tissue.² In the fetus, the dystrophic pathway is far more commonly reported. Infections, inflammation from autoimmune attack, and loss of blood supply all destroy patches of heart muscle, and calcium fills the resulting dead zones. Metastatic calcification is rarer prenatally but can occur when a genetic disorder throws off mineral metabolism.

Infections That Cross the Placenta

Certain infections in the mother can cross the placenta and directly invade fetal tissues, and the heart is one of the organs most often affected. When a virus or parasite reaches the fetal myocardium, it triggers inflammation, cell death, and subsequent calcification of the damaged areas. The central nervous system and the heart are the two sites where calcified lesions show up most frequently during fetal infection, often alongside other signs such as fluid buildup around the heart, growth restriction, and abnormal amniotic fluid volume.³

The infections most associated with this picture belong to a group sometimes referred to as TORCH: toxoplasmosis, rubella, cytomegalovirus (CMV), and herpes simplex virus (HSV), among others. Herpes simplex type II, for example, has been specifically documented as a cause of fetal myocardial calcification, with the pattern of calcification in the heart muscle serving as a distinctive ultrasound marker of in-utero HSV-II infection.⁴ CMV and toxoplasmosis produce similar damage, though they tend to affect the brain more prominently. In all of these infections, the calcification itself is a downstream consequence of tissue destruction rather than a primary event.

Maternal Autoimmune Antibodies

A mother’s immune system can inadvertently damage her baby’s heart even in the absence of any infection. In neonatal lupus syndrome, specific maternal autoantibodies called anti-SSA/Ro and anti-SSB/La cross the placenta and target fetal heart tissue. The best-known consequence is congenital heart block, which affects roughly one to two percent of exposed pregnancies. But these antibodies can also cause calcification in less expected places: the heart valves, the structures that anchor valve leaflets, and the walls of the great vessels leaving the heart.⁵

What makes this category tricky is that the mother herself may feel perfectly healthy. In one reported case, a fetus at 20 weeks showed multiple calcifications inside a structurally normal heart, including the pulmonary valve and the chords of both the mitral and tricuspid valves, yet the mother had no symptoms of autoimmune disease. She tested strongly positive for anti-SSA/Ro and anti-SSB/La antibodies only after the fetal findings prompted testing.⁵ The antibodies can also cause inflammation in and around the atrioventricular node, leading to calcification and fibrosis in that region, which is the tissue responsible for conducting electrical signals through the heart.⁶

Placental pathology can compound the cardiac damage. In pregnancies affected by antiphospholipid antibodies, including anticardiolipin antibodies, the placenta itself can develop severe clotting and infarction, depriving the fetus of oxygen and nutrients and sometimes leading to intrauterine death. These placental effects are separate from, but can co-exist with, the direct antibody-mediated heart injury.

Genetic Disorders of Calcification

Some fetuses are genetically predisposed to deposit calcium in their blood vessels and heart tissue. The most studied of these is generalized arterial calcification of infancy, or GACI, a rare inherited condition in which calcium accumulates throughout the walls of arteries, including those feeding and leaving the heart. GACI is usually caused by mutations in the ENPP1 gene, though mutations in a second gene, ABCC6, can produce a similar picture.⁷ The condition is inherited in an autosomal recessive pattern, meaning both parents carry one copy of the mutated gene without being affected themselves.

ENPP1 produces an enzyme that generates pyrophosphate, a molecule the body uses as a natural brake on calcification. When both copies of the gene are non-functional, pyrophosphate levels drop and calcium-phosphate crystals form unchecked in vessel walls. This can be detected remarkably early in pregnancy. One case documented calcification of the aorta and pulmonary trunk in a fetus at just 15 weeks, with exome sequencing confirming a pathogenic ENPP1 variant.⁸ The disease carries high morbidity and mortality in early life, making prenatal genetic confirmation valuable for family counseling.

Keutel syndrome is another rare genetic condition linked to cardiovascular calcification, though it tends to be recognized later in childhood rather than prenatally. It is caused by loss-of-function mutations in the gene for matrix Gla protein, or MGP, which normally acts as a calcification inhibitor in cartilage and blood vessels. Affected individuals develop abnormal calcification of cartilage throughout the body along with cardiovascular defects that can include pulmonary artery narrowing and, in some cases, arterial calcification.⁹ While Keutel syndrome is primarily a postnatal diagnosis, its underlying biology shares a common thread with GACI: both involve defective molecular machinery that normally prevents minerals from depositing in soft tissues.¹⁰

Endocardial Fibroelastosis

Endocardial fibroelastosis, or EFE, is a condition in which the inner lining of the heart thickens with fibrous and elastic tissue, eventually impairing the ventricles’ ability to pump. While EFE is not solely a calcification disorder, subendocardial calcifications are a recognized feature. Ultrasound shows a characteristic increase in the brightness of the endocardial surface along with thickened valves and reduced ventricular function.¹¹

EFE can arise from several different insults. Autoimmune antibody exposure is one established pathway: the same anti-SSA/Ro antibodies discussed earlier can trigger inflammation in the endocardium that evolves into fibroelastosis. But EFE also develops in some fetuses with structural heart defects, particularly those involving obstruction to outflow from the left side of the heart. In those cases, abnormal pressure and flow patterns damage the endocardial lining, which responds with fibrosis and, eventually, calcium deposition. The calcifications tend to concentrate in the subendocardial layer and around the papillary muscles and chordae that support the heart valves.⁶

Toxic Exposures and Maternal Drug Use

Substances that reach the fetus through the mother’s bloodstream can damage heart tissue directly, setting off dystrophic calcification. Cocaine is the best-documented example. It causes intense constriction of blood vessels, and in a developing fetus that effect can cut off blood flow to segments of heart muscle, causing cell death. Two pregnancies complicated by early cocaine use were reported with fetal myocardial calcification, with researchers concluding that the vascular and toxic effects of the drug were the likely cause of myocardial necrosis followed by calcification.¹²

Warfarin, a blood thinner used for conditions like mechanical heart valves or clotting disorders, poses a different kind of risk. It works by interfering with vitamin K, and vitamin K is essential not just for blood clotting but for normal skeletal and vascular development. When a pregnant woman takes warfarin, the drug can induce a condition called chondrodysplasia punctata in the fetus, characterized by abnormal calcification of cartilage. The teratogenic effects go beyond simple anticoagulation: warfarin disrupts several vitamin K-dependent developmental signaling pathways involved in skeletal, vascular, and neural development.¹³ While the primary target is cartilage rather than the myocardium, the vascular calcification that warfarin promotes is well documented in other contexts, and the overlap between disrupted mineral regulation and fetal cardiovascular development remains an area of concern.¹⁴

Maternal health conditions also contribute. Diabetes and high blood pressure have both been associated with fetal heart calcification, likely through their effects on placental blood flow and the metabolic environment surrounding the developing fetus. These associations are less well characterized in the literature than infections or genetic disorders, but they appear in clinical reviews as recognized contributing factors.

When Twin Pregnancies Complicate the Picture

Twin-twin transfusion syndrome, or TTTS, creates an unusual hemodynamic situation in which one identical twin (the “recipient”) receives too much blood through shared placental connections while the other (the “donor”) receives too little. The recipient twin’s heart has to handle a persistent volume overload that can lead to heart failure. In rare cases, this stress triggers arterial calcification, particularly in the aorta and pulmonary trunk.

One documented case involved a TTTS recipient twin who developed progressive calcification of the great vessels even after successful surgery to correct the placental blood-sharing imbalance. Genetic testing revealed the twin carried a single-copy variant in ABCC6, one of the genes associated with GACI. While a single copy is normally harmless, researchers speculated that the hemodynamic stress of TTTS may have unmasked a vulnerability that a two-copy carrier would never experience, a potential gene-environment interaction.¹⁵ This case is a reminder that fetal heart calcification sometimes has more than one contributing cause acting in tandem.

How Fetal Heart Calcification Is Detected

Prenatal ultrasound is the primary tool. Fetal cardiac calcifications appear as bright, echogenic areas within the heart walls, valves, or vessel walls, and they tend to be detected during the mid-pregnancy anatomy scan, typically between 18 and 22 weeks of gestation.¹ When the calcifications are extensive, they usually come with impaired cardiac function that is visible on the scan as well, including poor contractility and sometimes fluid accumulation around the heart.

One important distinction that sonographers and parents need to understand is the difference between true cardiac calcification and an echogenic intracardiac focus, or EIF. An EIF is a small bright spot inside the fetal heart, usually in the left ventricle, that represents a tiny mineral deposit on one of the papillary muscles. EIFs are common, appearing in a significant minority of routine mid-pregnancy scans, and the vast majority are completely harmless. They have historically been flagged as a soft marker for certain chromosomal conditions, but in an otherwise normal scan they rarely warrant alarm. True cardiac calcification, by contrast, involves larger, more diffuse deposits across the myocardium, endocardium, or valves, and it is associated with measurably impaired heart function. A systematic review of EIF data found that right-sided EIFs were associated with cardiac abnormality at a higher rate than left-sided ones, but even so, the overall percentage remained small.¹⁶ The clinical significance of an EIF and true diffuse cardiac calcification are worlds apart.

When genuine calcification is found, the diagnostic workup broadens. Maternal blood tests for TORCH infections, autoimmune antibody panels for anti-SSA/Ro and anti-SSB/La, and genetic testing of the fetus through amniocentesis or chorionic villus sampling all become part of the picture. Fetal echocardiography provides a more detailed look at heart structure and function than a standard anatomy scan, and it helps determine how severely the calcification has compromised the heart’s pumping ability.

Why the Cause Matters for Prognosis

Not all fetal heart calcification carries the same outlook. When the calcification is caused by a treatable or self-limited infection, the prognosis depends largely on how early the infection is caught and whether the heart damage is extensive enough to impair function long-term. When the cause is maternal autoimmune antibodies, the heart block that accompanies valvular calcification sometimes progresses even after delivery, and some affected babies need pacemakers, but many survive with treatment.

Genetic disorders like GACI carry a more guarded prognosis. The calcification tends to be progressive and widespread, and without intervention it can lead to severe cardiovascular compromise in the newborn period. Treatment with bisphosphonates, drugs that slow down mineral deposition, has been tried in GACI with some success, but outcomes are variable. Prenatal identification via genetic testing gives families the chance to plan delivery at a center equipped to begin treatment immediately.

For EFE, the prognosis depends on the underlying cause and how much of the endocardium is affected. When fibroelastosis and calcification are extensive and biventricular, the outcomes tend to be poor. When the condition is caught early and is localized, there is more room for intervention, though options remain limited in the fetal period.

Warfarin and Pregnancy Planning

Because warfarin crosses the placenta and interferes with vitamin K-dependent processes critical to fetal development, women who require long-term anticoagulation face a real dilemma when planning pregnancy. The highest-risk window for fetal warfarin syndrome is the first trimester, roughly between six and twelve weeks of gestation, when skeletal and vascular structures are forming. Guidelines generally recommend switching to heparin-based anticoagulants, which do not cross the placenta, during at least the first trimester and often for the entire pregnancy. The disrupted pathways go well beyond clotting: warfarin impairs signaling cascades involved in bone, cartilage, and blood vessel formation.¹³ The calcification component, whether in cartilage, arteries, or heart tissue, is essentially the fetus losing its natural defense against mineral deposition in soft tissues because the enzyme that activates matrix Gla protein and other calcification inhibitors has been knocked out by the drug.¹⁴

This is one of the more actionable pieces of information around fetal calcification: it is one of the few causes that is entirely preventable with appropriate medication management before conception. Women with mechanical heart valves, recurrent clotting, or antiphospholipid syndrome should work with both a cardiologist and a maternal-fetal medicine specialist well before becoming pregnant to develop a safe anticoagulation plan.

Rare Syndromic Causes Still Being Mapped

The genetic landscape of inherited calcification disorders is broader than GACI and Keutel syndrome alone. Researchers have grouped these conditions into categories based on the mechanism driving the calcification. One group involves an imbalance in the ratio of inorganic phosphate to pyrophosphate, the chemical brake on mineralization. GACI, pseudoxanthoma elasticum, and a handful of other conditions fall here. A second group involves overactive interferon signaling, as seen in Singleton-Merten syndrome. And a third group includes disorders like Keutel syndrome and a rare form of Gaucher disease where the calcification pathway does not fit neatly into either of the first two buckets.¹⁰

Most of these conditions are vanishingly rare, but understanding them has real practical value. The gene variants responsible sometimes overlap: ABCC6 mutations cause both GACI and pseudoxanthoma elasticum depending on context, and heterozygous carriers who would normally be unaffected may develop problems under unusual stress, as the TTTS case described earlier illustrates.¹⁵ As whole-exome and whole-genome sequencing become more accessible in prenatal settings, the ability to identify these rare conditions before birth is improving rapidly. The challenge is less about detecting the calcification on ultrasound and more about figuring out which of many possible genetic and environmental causes is responsible in each individual case.